Education
About Us
Working with TipRanks
Follow Us
Roche Holding (DE:RHO6)
FRANKFURT:RHO6
RHO6 Stock Chart & Stats
€50.40
-€0.54(-1.51%)
At close: 4:00 PM EST
€50.40
-€0.54(-1.51%)
Day’s Range― - ―
52-Week Range€31.80 - €50.96
Previous CloseN/A
Volume0.00
Average Volume (3M)65.00
Market Cap
€323.76B
Enterprise Value€320.02B
Total Cash (Recent Filing)€15.49B
Total Debt (Recent Filing)€31.67B
Price to Earnings (P/E)23.4
Beta0.37
Next Earnings
Jul 23, 2026EPS Estimate
1.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.15
Shares Outstanding5,620,501,500
10 Day Avg. Volume81
30 Day Avg. Volume65
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)7.76
Price to Sales (P/S)4.47
P/FCF Ratio19.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€48.97Price Target Upside-2.83% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEarly trontinemab data shows competitive amyloid clearance and improved ARIA rate versus peers, but clinical outcomes will determine success.
Financial PerformanceRoche's model was updated and numbers raised post recent business trends, with sales and EPS growth estimates increased.
Product EfficacyGazyva showed potential best-in-class profile in lupus nephritis and is likely to be the starter therapy of choice versus GSK's Benlysta.
Bears Say
Clinical Trial SafetyThere was a case of fatal cerebral macrohemorrhage in Part 2, leading to updated trial criteria to exclude patients with superficial siderosis.
Placebo ResponseThe high placebo response rate in males was notable, where placebo achieved a 66.7% complete renal response compared to 42.9% for Gazyva.
Roche Holding News
RHO6 FAQ
What was Roche Holding’s price range in the past 12 months?
Roche Holding lowest stock price was €31.80 and its highest was €50.96 in the past 12 months.
What is Roche Holding’s market cap?
Roche Holding’s market cap is €323.76B.
When is Roche Holding’s upcoming earnings report date?
Roche Holding’s upcoming earnings report date is Jul 23, 2026 which is in 154 days.
How were Roche Holding’s earnings last quarter?
Roche Holding released its earnings results on Jan 29, 2026. The company reported €1.154 earnings per share for the quarter, beating the consensus estimate of €1.137 by €0.017.
Is Roche Holding overvalued?
According to Wall Street analysts Roche Holding’s price is currently Overvalued.
Does Roche Holding pay dividends?
Roche Holding does not currently pay dividends.
What is Roche Holding’s EPS estimate?
Roche Holding’s EPS estimate is 1.49.
How many shares outstanding does Roche Holding have?
Roche Holding has 5,620,501,500 shares outstanding.
What happened to Roche Holding’s price movement after its last earnings report?
Roche Holding reported an EPS of €1.154 in its last earnings report, beating expectations of €1.137. Following the earnings report the stock price went up 2.73%.
Which hedge fund is a major shareholder of Roche Holding?
Currently, no hedge funds are holding shares in DE:RHO6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roche Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€48.97 (-2.83% Downside)
€48.97 (-2.83% Downside)
Blogger Sentiment
Bullish
DE:RHO6 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.62%
12-Months-Change
Fundamentals
Return on Equity
39.72%
Trailing 12-Months
Asset Growth
13.16%
Trailing 12-Months
Company Description
Roche Holding
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
RHO6 Company Deck
RHO6 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call struck a broadly positive tone: Roche reported solid FY2025 financial results (7% sales growth, +13% core operating profit) and delivered exceptional pipeline momentum with multiple Phase III and regulatory successes (including record progression of NMEs to Phase III and major readouts for fenebrutinib and giredestrant). Management reiterated disciplined capital allocation, upgraded guidance execution and substantial near-term commercial opportunities (AXELIOS sequencing, diagnostics menu expansion, several on-market growth drivers). Key headwinds include significant Diagnostics disruption from China pricing reforms (CHF ~579m impact), weaker operating cash flow driven by working capital build, an increased tax burden affecting EPS momentum, currency and tariff pressures, and regulatory/safety uncertainty in the BTK space. On balance, the quantity and quality of positive clinical readouts, approvals and commercial traction materially outweigh the operational and macro headwinds reported.View all DE:RHO6 earnings summariesRHO6 Stock 12 Month Forecast
Average Price Target
€48.97
▼(-2.83% Downside)
Technical Analysis
Options Prices
Currently, No data available
---